Post by Xtalks Pharmaville

For emerging biotech, talent is the dominant location factor. Everything else is downstream. That is the framing CERo Therapeutics CEO Chris Ehrlich shared in an exclusive Xtalks interview about why established US biotech clusters remain difficult to recreate and how the next phase of biotech growth is becoming more distributed. "There are two major factors to think about relative to setting up your facilities, whether you're going to be at a headquarters or you're going to be manufacturing something," Ehrlich explained. "One, which is really the most important by far, is talent." That talent reality looks different for biologics, gene therapies and engineered cell therapies than it does for small molecule programs. Small molecule manufacturing can often be outsourced. Complex biologics manufacturing cannot. That is why South San Francisco, San Diego and Boston remain the structural defaults for advanced therapy programs. "Talent is evenly distributed relative to the quality of the science," Ehrlich said. "However, the difference becomes where are the places where they actually have people who've got experience in building and running these companies so you're not reinventing the wheel." CERo's lead candidate CER-1236, an engineered T cell therapeutic, is being evaluated in a Phase I/Ib trial in AML, with the first site at MD Anderson Cancer Center, led by Abhishek Maiti, MD. The FDA granted CER-1236 Fast Track designation for AML in 2025. Read the full Xtalks interview on Pharmaville. https://lnkd.in/dfMiyiwb #Biotech #Oncology #CellTherapy #ClinicalTrials #LifeSciences